Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company, is scheduled to participate in the Stifel 2025 Healthcare Conference with a fireside chat featuring CEO Jennifer Good and Chief Development Officer James Cassella. The event will take place on November 11, 2025, at 3:20 p.m. ET in New York City, where the executives will also engage in investor meetings. Trevi is focused on developing Haduvio™ (oral nalbuphine ER) aimed at treating chronic cough associated with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC).

Haduvio is notable for being the first investigational therapy to demonstrate a statistically significant reduction in cough frequency during clinical trials, particularly for patients suffering from chronic cough linked to IPF and RCC. This drug works by targeting opioid receptors as a kappa agonist and mu antagonist (KAMA), aiming to control the chronic cough reflex through both central and peripheral mechanisms. It is important to note that nalbuphine is not classified as a controlled substance by the U.S. Drug Enforcement Administration.

Chronic cough remains a significant unmet medical need, with approximately 150,000 U.S. patients diagnosed with IPF, of whom nearly two-thirds experience uncontrolled coughing. Furthermore, around 228,000 patients with non-IPF ILD are affected, with a significant portion also suffering from uncontrolled cough issues. RCC, impacting an estimated 2-3 million individuals in the U.S., is characterized by a persistent cough lasting over eight weeks, regardless of underlying treatment. Both conditions can severely affect patients' quality of life and lead to greater morbidity and healthcare utilization. Trevi intends to propose Haduvio as the proprietary name for this investigational therapy, although its safety and efficacy remain unverified by regulatory authorities. More information can be found on Trevi's official website and social media platforms.

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company, is gearing up for significant visibility at the upcoming Stifel 2025 Healthcare Conference. With its investigational therapy Haduvio™ showing promising results for chronic cough in idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (ILD), and refractory chronic cough (RCC), this event presents an opportune moment for investors to assess its potential.

Trevi's Haduvio™ is notable as the only investigational therapy to demonstrate a statistically significant reduction in cough frequency in both IPF and RCC patients during clinical trials. Given the large patient populations—approximately 150,000 with IPF and up to 3 million suffering from RCC in the U.S.—the unmet medical need is stark. Patients with chronic cough experience debilitating cough frequency, leading to declining quality of life and increased morbidity. This highlights an advantageous market void that Haduvio could fill, assuming it progresses smoothly through clinical evaluation and regulatory scrutiny.

Participating in the Stifel conference allows Trevi's leadership to articulate its strategic vision, highlight trial data, and engage directly with potential investors. It's essential for stakeholders to monitor updates and developments from this event closely, as investor sentiment could shift based on perceived progress or setbacks articulated during these discussions.

From an investment perspective, Trevi Therapeutics presents a compelling narrative characterized by potential high rewards amid significant risks typical of biopharmaceutical development. Investors should evaluate their risk tolerance and consider the long-term growth prospects tied to Haduvio's clinical advancement. Keeping abreast of upcoming clinical trial outcomes and regulatory feedback will be crucial in making informed investment decisions regarding Trevi Therapeutics in the coming months.